PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Passage BIO, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$3.58+0.08 (+2.29%)
Close on Oct 19, 2026
- Market cap
- $11.49M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.49 (−55.64%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $11.49M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.58
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$36.11M
- EPS, diluted
- -$11.32
- Book value per share
- $1.39
- Diluted shares
- 3M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
-$39.02M
Net income
-$36.11M
EPS, diluted
-$11.32
Free cash flow
–
Reported periodTrailing twelve months